Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q05586

UPID:
NMDZ1_HUMAN

ALTERNATIVE NAMES:
Glutamate [NMDA] receptor subunit zeta-1; N-methyl-D-aspartate receptor subunit NR1

ALTERNATIVE UPACC:
Q05586; A6NLK7; A6NLR1; C9K0X1; P35437; Q12867; Q12868; Q5VSF3; Q5VSF4; Q5VSF5; Q5VSF6; Q5VSF7; Q5VSF8; Q9UPF8; Q9UPF9

BACKGROUND:
Glutamate receptor ionotropic, NMDA 1, known alternatively as Glutamate [NMDA] receptor subunit zeta-1 or N-methyl-D-aspartate receptor subunit NR1, is integral to neurotransmission. It forms part of the NMDA receptor complex, acting as a ligand-gated ion channel with significant implications for calcium signaling and synaptic activity. Its function is essential for cognitive processes such as learning and memory.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting this protein are associated with a spectrum of neurodevelopmental disorders, including various forms of developmental and epileptic encephalopathy. The exploration of Glutamate receptor ionotropic, NMDA 1's role offers promising avenues for the development of novel treatments for these disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.